Drawing for SEQIRUS

USPTO serial 86727032

SEQIRUS

Reviewed by CopyMark Law Group

Reg. 5184313Status 705Renewal
Filing date
Status date
Registration date
Apr 18, 2017
Examiner
SNABB, SANDRA MARIE
Law office
—

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with SEQIRUS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nancy Sabarra

Nancy Sabarra Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th FloorNew York, NY 10036UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001[ Chemical and biological reagents for scientific and non-medical purposes; cell cultures and media for laboratory, scientific and research use; test kits for scientific and non-medical laboratory use for anti-body screening, blood grouping or detection of specific blood cells, antigens and immunoglobulin subtypes; chemical preparations for scientific and industrial purposes; diagnostic and testing agents for scientific and non-medical purposes; Chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells ]SECTION 8 - CANCELLED—
005Pharmaceutical preparations and substances for the [ treatment and ] prevention of [ blood disorders, bleeding disorders, and ] diseases caused by [ bacteria and ] viruses; vaccines; [ blood products, namely, immunoglobulins for medical or clinical use; medicated serums for the treatment of influenza; anti-virals; ] influenza vaccines; adjuvants and antigens for medical purposes; [ blood products, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic use; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; test kits, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, Rheysys Factor D Antigen reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies and Immunoglobulin subtypes; ] pharmaceutical preparations, namely, therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases [ ; pharmaceutical preparations, namely, reagents for medical and clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes ]ACTIVE—
044[ Medical services; ] medical information services; [ health care services; health care information services, namely, internet-based health care information services; providing medical information concerning blood products; ] providing medical information concerning vaccines [, anti-venoms and immunohematology products, namely, diagnostic reagents; patient support services, namely, providing an Internet-based database of patient medical information, where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 18, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Apr 16, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Apr 16, 2024C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Apr 16, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 18, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Apr 18, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 25, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 25, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 18, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 18, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 18, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 13, 2017DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Mar 13, 2017AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 6, 2017IUCNNOTICE OF ALLOWANCE CANCELLED—
Mar 6, 2017D1BRTEAS DELETE 1(B) BASIS RECEIVED—
Feb 7, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 13, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 13, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 23, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 10, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 3, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 31, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 31, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 24, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 20, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 20, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 20, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 1, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 1, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 25, 2016ALIEASSIGNED TO LIE—
Aug 18, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 1, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 1, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 24, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 3, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 2, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 2, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 2, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 3, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 3, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 3, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2015DOCKASSIGNED TO EXAMINER—
Aug 21, 2015MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Aug 20, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 20, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance